| GlaxoSmithKline AG - Wellbutrin XR 300 mg, Retardtabletten | | 57803 | | 02 | | Wellbutrin XR 300 mg | | Retardtabletten | | N06AX12 | | | | 01.11.2007 | | |
| | Composition | | bupropioni hydrochloridum 300 mg, poly(alcohol vinylicus), glyceroli dibehenas, Überzug: ethylcellulosum, povidonum K 90, macrogolum 1450, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, silica colloidalis hydrica, triethylis citras, Drucktinte: lacca, E 172 (nigrum), ammonii hydroxidum, pro compresso obducto. | | Packungsbestandteile | | Comprimés retards | | | | | Principe actif | Concentr. |
|---|
| Bupropion Hydrochloride | 300 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Bupropion Hydrochloride | 300 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| | | | | | | | | | | | | | | color. | | | | Überzug | | | | | | | | | | | | Drucktinte | | Macrogol | 1450 | | | | | | | | 90 | | | | | | | | | | | | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 008 | 30 Comprimé(s) | 23.10 | 41.40 | B | LS | Non |
|
|
